📣 VC round data is live. Check it out!
- Public Comps
- Niagen Bioscience
Niagen Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Niagen Bioscience and similar public comparables like Medy-Tox, Chong Kun Dang Holdings, Zhejiang Shouxiangu, Vita Life Sciences and more.
Niagen Bioscience Overview
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Founded
2000
HQ

Employees
104
Website
Financials (LTM)
EV
$228M
Valuation Multiples
Start free trialNiagen Bioscience Financials
Niagen Bioscience reported last 12-month revenue of $134M and EBITDA of $23M.
In the same LTM period, Niagen Bioscience generated $87M in gross profit, $23M in EBITDA, and $18M in net income.
Revenue (LTM)
Niagen Bioscience P&L
In the most recent fiscal year, Niagen Bioscience reported revenue of $129M and EBITDA of $21M.
Niagen Bioscience is profitable as of last fiscal year, with gross margin of 64%, EBITDA margin of 17%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Niagen Bioscience Stock Performance
Niagen Bioscience has current market cap of $292M, and enterprise value of $228M.
Market Cap Evolution
Niagen Bioscience's stock price is $3.67.
Niagen Bioscience share price decreased by 22.2% in the last 30 days, and by 66.1% in the last year.
Niagen Bioscience has an EPS (earnings per share) of $0.22.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $228M | $292M | -0.8% | -22.2% | -27.3% | -66.1% | $0.22 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNiagen Bioscience Valuation Multiples
Niagen Bioscience trades at 1.7x EV/Revenue multiple, and 10.1x EV/EBITDA.
EV / Revenue (LTM)
Niagen Bioscience Financial Valuation Multiples
As of May 20, 2026, Niagen Bioscience has market cap of $292M and EV of $228M.
Niagen Bioscience has a P/E ratio of 16.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Niagen Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Niagen Bioscience Margins & Growth Rates
Niagen Bioscience grew revenue by 10% and EBITDA by 15% in the last fiscal year.
In the most recent fiscal year, Niagen Bioscience reported gross margin of 64%, EBITDA margin of 17%, and net margin of 13%.
Niagen Bioscience Margins
Niagen Bioscience Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Niagen Bioscience Operational KPIs
Niagen Bioscience's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.7M for the same period.
Niagen Bioscience's Rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Niagen Bioscience's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Niagen Bioscience Competitors
Niagen Bioscience competitors include Medy-Tox, Chong Kun Dang Holdings, Zhejiang Shouxiangu, Vita Life Sciences, FitLife Brands, Venture Life Group, Promopharm, Grape King Bio, Hyundai Bioland Co and Enzymatica.
Most Niagen Bioscience public comparables operate across Nutraceuticals & Cosmeceuticals.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | 2.7x | 24.6x | 19.4x | |||
| 0.7x | — | 4.9x | — | |||
| 4.3x | 4.3x | 12.6x | — | |||
| 1.1x | — | 6.8x | — | |||
| 1.7x | 1.5x | 9.6x | 9.2x | |||
| 1.3x | 1.0x | 8.2x | 6.0x | |||
| 0.9x | — | 7.8x | — | |||
| 1.1x | 1.1x | 4.0x | — | |||
This data is available for Pro users. Sign up to see all Niagen Bioscience competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Niagen Bioscience
| When was Niagen Bioscience founded? | Niagen Bioscience was founded in 2000. |
| Where is Niagen Bioscience headquartered? | Niagen Bioscience is headquartered in United States. |
| How many employees does Niagen Bioscience have? | As of today, Niagen Bioscience has over 104 employees. |
| Who is the CEO of Niagen Bioscience? | Niagen Bioscience's CEO is Robert N. Fried. |
| Is Niagen Bioscience publicly listed? | Yes, Niagen Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Niagen Bioscience? | Niagen Bioscience trades under NAGE ticker. |
| When did Niagen Bioscience go public? | Niagen Bioscience went public in 2008. |
| Who are competitors of Niagen Bioscience? | Niagen Bioscience main competitors include Medy-Tox, Chong Kun Dang Holdings, Zhejiang Shouxiangu, Vita Life Sciences, FitLife Brands, Venture Life Group, Promopharm, Grape King Bio, Hyundai Bioland Co, Enzymatica. |
| What is the current market cap of Niagen Bioscience? | Niagen Bioscience's current market cap is $292M. |
| What is the current revenue of Niagen Bioscience? | Niagen Bioscience's last 12 months revenue is $134M. |
| What is the current revenue growth of Niagen Bioscience? | Niagen Bioscience revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Niagen Bioscience? | Current revenue multiple of Niagen Bioscience is 1.7x. |
| Is Niagen Bioscience profitable? | Yes, Niagen Bioscience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Niagen Bioscience? | Niagen Bioscience's last 12 months EBITDA is $23M. |
| What is Niagen Bioscience's EBITDA margin? | Niagen Bioscience's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Niagen Bioscience? | Current EBITDA multiple of Niagen Bioscience is 10.1x. |
| What is the current FCF of Niagen Bioscience? | Niagen Bioscience's last 12 months FCF is $18M. |
| What is Niagen Bioscience's FCF margin? | Niagen Bioscience's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Niagen Bioscience? | Current FCF multiple of Niagen Bioscience is 12.6x. |
| How many companies Niagen Bioscience has acquired to date? | Niagen Bioscience hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Niagen Bioscience has invested to date? | Niagen Bioscience hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Niagen Bioscience
Lists including Niagen Bioscience
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.